Reading PTCT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PTCT free→Reading PTCT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PTCT free→
NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and management's recent track record has been steady, with capital-friendly moves. However, the company was unprofitable over the past year, so its earnings quality can't be assessed. Peer multiples imply a price about 46% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak or earnings quality is fragile. Key factors to watch include guidance changes and sector trends, particularly the performance of bellwethers like VRTX, REGN, and ARGX. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $76.77. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $77 the market pays 3× p/s — above the 3× p/s peer median but in line with its own 3× history. That premium reflects a durable franchise our peer-anchored $134 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $82–$120. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 43% below a flat-multiple fair value, ahead of our forecast of about -60%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.17x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.46 → $0.33 (+172.5% / 30d). 0 raised, 0 cut, 3 covering analysts.
1 upgrade, 0 downgrades / 30d, 0 maintained. 73% of analysts rate Buy.
1 PT revisions / 30d. Avg target 21.5% above current price.
1 positive, 0 negative / 30d. See F4 management tile for the event list.
Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$150.
How much price usually moves either way.
On a bad day, this stock has moved -$352.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,717.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
As of June 16, 2026, the signal label changed to mixed, indicating a shift in sentiment. The risk dimension fell, suggesting a decrease in perceived risk. The earnings quality remains loss-making, and the management dimension is stable. The sector backdrop is a headwind, which may impact performance.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Total revenue results will indicate if the company is on track to meet its $1.08-$1.18 billion guidance.
Confirms:Q2 2026 total revenue exceeds $300 million.
Disproves:Q2 2026 total revenue falls below $250 million.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PTCT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. On June 15, 2026, PTC Therapeutics, Inc. (the “Company”) issued a press release announcing the pricing of its previously announced offering (the “Offering”) of $500.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2031 (the “Notes”). The Company also granted the initial purchasers an option to purchase, within the 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $50.0 million aggregate principa…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$82.00 – $120.00 (median $92.00) · 7 analysts · as of 2026-05-27
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PTCT PTC Therapeutics, Inc. | Typical Show detailsSector percentile: 67 of 100 | inexpensive | moderate |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 89 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 75 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 67 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 61 of 100 | fair | low |
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
PTC aims to increase total revenue to a range of $1.08 to $1.18 billion for the fiscal year 2026.
PTC has raised its product revenue guidance for 2026 to a range of $750 to $850 million.
PTC aims to manage its R&D and SG&A expenses within the range of $680 to $720 million for 2026.
Why it matters: An update on revenue guidance will show if the company is on track to meet its goals. This is key for investor confidence.
Confirms:Management raises total revenue guidance to $1.08 billion or more for 2026.
Disproves:Management lowers total revenue guidance to less than $1.08 billion for 2026.
Why it matters: If revenue growth drops below its median, it signals a potential slowdown in the healthcare sector. This could impact PTC's performance.
Confirms:Healthcare revenue growth reported below the median of 1% year over year.
Disproves:Healthcare revenue growth remains above the median of 1% year over year.
Why it matters: Results will show how well votoplam works for Huntington's disease. This will affect future revenue.
Confirms one read:Positive results from the Phase 3 INVEST-HD study show a big slowdown in disease progression.
Confirms the other:Negative results from the Phase 3 INVEST-HD study show no real benefit.
Why it matters: Keeping expenses between $680 million and $720 million shows they manage costs well.
Confirms:Reported R&D and SG&A expenses are at or below $680 million.
Disproves:Reported R&D and SG&A expenses exceed $720 million.
Why it matters: Starting this study will show progress in the Friedreich's ataxia program. It may lead to future revenue.
Confirms:PTC will start the open-label vatiquinone study in Q3 2026.
Disproves:PTC delays the start of the open-label vatiquinone study past Q3 2026.
Director — Alethia Young: Ms. Young resigned from the Board to focus on other commitments but will continue as a consultant.
Results of Operations and Financial Condition. On May 7, 2026, PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") and is incorporated by reference into this
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 24, 2026, PTC Therapeutics, Inc., (the “Company”) appointed Jessica Chutter to its board of directors (the “Board”), effective immediately, filling a vacancy on the Board. Ms. Chutter will serve as a Class I director with a term expiring at the annual meeting of stockholders to be held in 2026. Ms. Chutter has over 40 years’ experience in…
Results of Operations and Financial Condition. On February 19, 2026, PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") and is incorporated by reference into this